About Synolo Therapeutics
Synolo Therapeutics, an early-stage biotechnology company launched by RA Ventures, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies that yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities. Synolo was founded by pioneers in the field of protein design and engineering, synthetic biology, DNA sequencing, immunology, and biologics drug discovery and development. About RA Capital: RA Capital Management funds and builds healthcare and life science companies using an evidence-based...
Leadership at Synolo Therapeutics
The team at the top of the org chart.
Miguel Arcinas
Chief Business Officer